GlassScriptPhysician profile
Robert S Bradford
NPI 1871557165
$15,970.36
in general payments reported to CMS, 2019-2025
54 companies · $2,513 in 2025
The $2,513 reported for 2025 was more than what 84% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,993 · 2020: $1,454 · 2021: $2,239 · 2022: $2,110 · 2023: $2,212 · 2024: $2,449 · 2025: $2,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,989 · Travel and Lodging: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,989.01 |
| Travel and Lodging | $185.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,357.65 | 2019-2020 | |
| Astellas Pharma US INC | $1,322.62 | 2019-2025 | Xtandi, Veozah, Myrbetriq |
| Pfizer INC. | $1,027.05 | 2019-2025 | |
| Janssen Biotech, INC. | $894.66 | 2019-2025 | Erleada, Akeega |
| Medtronic, INC. | $805.20 | 2021-2025 | Interstim |
| Boston Scientific Corporation | $763.37 | 2019-2025 | Spaceoar Vue System - 10ml, Axonics, Ams 700 Cxr Rte Kit |
| Procept Biorobotics Corporation | $733.37 | 2024-2025 | Aquabeam System |
| Abbvie INC. | $731.33 | 2019-2025 | Botox, Lupron Depot |
| Endo Pharmaceuticals INC. | $725.46 | 2019-2024 | Edex, Xiaflex, Aveed |
| Dendreon Pharmaceuticals LLC | $609.10 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $520.53 | 2023-2025 | Gemtesa, Orgovyx |
| Allergan, INC. | $514.16 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $511.94 | 2021-2024 | Prolaris |
| Axonics, INC. | $488.65 | 2020-2023 | Axonics, Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $434.91 | 2019-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $395.92 | 2021-2025 | Urolift, Barrigel |
| Coloplast Corp | $369.46 | 2019-2024 | |
| Amgen INC. | $358.34 | 2019-2023 | Xgeva |
| Ferring Pharmaceuticals INC. | $304.04 | 2019-2025 | Adstiladrin |
| Cook Medical LLC | $303.34 | 2019-2024 | Cook, Ncircle |
| Antares Pharma, INC. | $286.53 | 2019-2024 | Xyosted |
| Medtronic USA, INC. | $237.35 | 2019-2020 | |
| Blue Earth Diagnostics | $185.39 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $179.43 | 2022-2025 | |
| Tolmar Pharmaceuticals, INC. | $159.41 | 2020-2022 | |
| Olympus America INC. | $156.16 | 2023-2025 | Itind System |
| Endo USA, INC. | $155.49 | 2024-2025 | Xiaflex, Aveed, Edex |
| Urovant Sciences INC | $127.59 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $120.68 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Verity Pharmaceuticals INC. | $118.02 | 2022-2025 | Trelstar |
| Astrazeneca Pharmaceuticals LP | $102.75 | 2020-2021 | |
| Urogen Pharma, INC. | $95.47 | 2020-2025 | |
| Bioprotect Medical, INC. | $88.91 | 2025 | Bioprotect Balloon Implant System |
| Tempus Ai, INC | $73.19 | 2024-2025 | Xt Cdx |
| C. R. Bard, INC. & Subsidiaries | $72.80 | 2020 | |
| Accord Healthcare, INC. | $70.60 | 2022-2025 | |
| Tolmar, INC. | $69.81 | 2023-2024 | |
| Immunitybio, INC. | $61.12 | 2024-2025 | |
| Profound Medical Corp. | $54.32 | 2025 | Tulsa-Pro |
| Telix Pharmaceuticals | $50.23 | 2022-2023 | Illuccix |
| Clarus Therapeutics INC. | $45.39 | 2021 | |
| Myovant Sciences INC. | $40.36 | 2021-2022 | |
| Lsi Solutions INC | $39.90 | 2024 | Jnw Urtrac |
| Sun Pharmaceutical Industries INC. | $39.47 | 2022-2024 | |
| Metuchen Pharmaceuticals | $29.35 | 2020 | |
| Avadel Specialty Pharmaceuticals, LLC | $26.21 | 2019 | |
| Caris Mpi, INC. | $24.31 | 2025 | Mi Cancer Seek |
| Civco Medical Instruments | $22.81 | 2024 | |
| Mimedx Group, INC. | $19.91 | 2024 | |
| Progenics Pharmaceuticals, INC. | $18.39 | 2024 | |
| Alnylam Pharmaceuticals INC. | $14.32 | 2023 | Oxlumo |
| Travere Therapeutics, INC. | $13.59 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bradford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.